Promising Results from Alzheimer's Disease Passive Immunotherapy Support the Development of a Preventive Vaccine.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

18 citing papers in PubMed, 31 citations in OpenAlex.

1. Lecanemab for Patients With Early Alzheimer Disease: Bayesian Analysis of a Phase 2b Dose-Finding Randomized Clinical Trial.JAMA network open · 2023
   Trial
2. Classifications of Neurodegenerative Disorders Using a Multiplex Blood Biomarkers-Based Machine Learning Model.International journal of molecular sciences · 2020
   Trial
3. Cancer Hacks Neurodegeneration: Cystatin-C as a Bridge for Microglial Amyloid Clearance via TREM2.Research (Washington, D.C.) · 2026
   Article
4. Revolutionizing Neuroimmunology: Unraveling Immune Dynamics and Therapeutic Innovations in CNS Disorders.International journal of molecular sciences · 2024
   Review
5. The Dual Role of Amyloid Beta-Peptide in Oxidative Stress and Inflammation: Unveiling Their Connections in Alzheimer's Disease Etiopathology.Antioxidants (Basel, Switzerland) · 2024
   Review
6. Emerging Roles of Adaptive Immune Response in Alzheimer's Disease.Aging and disease · 2024
   Review
7. Novel Vaccine against Pathological Pyroglutamate-Modified Amyloid Beta for Prevention of Alzheimer's Disease.International journal of molecular sciences · 2023
   Article
8. Age-Related Alterations in Peripheral Immune Landscape with Magnified Impact on Post-Stroke Brain.Research (Washington, D.C.) · 2023
   Article
9. Desialylated Platelet Clearance in the Liver is a Novel Mechanism of Systemic Immunosuppression.Research (Washington, D.C.) · 2023
   Article
10. Aβ42 oligomer-specific antibody ALZ-201 reduces the neurotoxicity of Alzheimer's disease brain extracts.Alzheimer's research & therapy · 2022
    Article
11. A novel bio-inspired strategy to prevent amyloidogenesis and synaptic damage in Alzheimer's disease.Molecular psychiatry · 2022
    Article
12. Aducanumab Therapy to Treat Alzheimer's Disease: A Narrative Review.International journal of Alzheimer's disease · 2022
    Review
13. Peptide-Based Vaccines for Neurodegenerative Diseases: Recent Endeavors and Future Perspectives.Vaccines · 2021
    Review
14. FLAME: A computerized neuropsychological composite for trials in early dementia.Alzheimer's & dementia (Amsterdam, Netherlands) · 2020
    Article
15. Nonhuman Primate Model of Oculocutaneous Albinism withResearch (Washington, D.C.) · 2020
    Article
16. Dreaming of a New World Where Alzheimer's Is a Treatable Disorder.Frontiers in aging neuroscience · 2019
    Article
17. Therapeutic Potential of Neu1 in Alzheimer's Disease Via the Immune System.American journal of Alzheimer's disease and other dementias
    Review
18. Peptide vaccination for Alzheimer's disease: Immunological foundations, therapeutic potential, and translational barriers.Journal of Alzheimer's disease reports
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract